Caris Life Sciences Shares Plunge 9.1% After Supreme Court Tariff Ruling
Caris Life Sciences shares fell 9.1% after the Supreme Court ruled that the president lacks authority under the IEEPA to impose tariffs, exposing small-cap firms to intensified foreign competition. The court did not address whether the administration must refund over $130 billion already collected in emergency tariffs.
1. Supreme Court Restriction on Presidential Tariffs
In a landmark decision the Supreme Court held that the International Emergency Economic Powers Act does not grant the president authority to impose tariffs during peacetime, grounding its reasoning in separation-of-powers and affirming that tariff-setting power rests solely with Congress.
2. Caris Life Sciences Stock Reaction
Shares of Caris Life Sciences fell 9.1% on the ruling as investors reevaluated the small-cap’s competitive position, weighing the potential rollback of emergency tariffs and increased exposure to foreign rivals.
3. Competitive Pressure and Refund Uncertainty
The court did not mandate repayment of the $130 billion in emergency duties already collected, leaving uncertainty over refunds and signaling possible cost advantages for overseas producers that could pressure margins for Caris and similar small-cap firms.